Product
Veliparib + Lapatinib
1 clinical trial
1 indication
Indication
Triple Negative Breast CancerClinical trial
An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-22